Featuring the release of the Foundations for Open Scholarship Strategy Development document, the addition of citation data to Altmetric, the launch of Participation Reports by Crossref, and The Francis Crick Institute’s commitment to open access and preprints.
Featuring the launch of cloud-based technology that enables one-click access to research articles, the new supplement for publishing negative results, and the first publisher-owned open research platform.
Open access publishing of medical research is increasingly prevalent, but open access terminology is varied and confusing. Gold, green, bronze, hybrid, CC BY, CC BY-NC – what does it all mean, and what is the best type of open access? At the 14th Annual Meeting of the International Society of Medical Publication Professionals, a panel of stakeholders in medical publications met to discuss open access from different perspectives.
Featuring the plans of UK research funders to review their open access policies, indications that the EU is set to miss its open access target, blockchain technologies for peer review, and a new preprints highlighting service.
Featuring the EU Commission’s new open science role, a new tool to analyse the uptake of hybrid open access publishing, and results from the European University Association’s open access survey.
Featuring Vivli, a novel global clinical trial data sharing platform, MedArXiv, the preprint server for medicine, the BMJ’s new open access journal and the peer review distribution index.
Featuring an introduction to Metadata2020, reaction to proposals for EU copyright reform, Elsevier’s new data-sharing framework and initial decisions on the second Research Excellence Framework.
Use of preprints is increasing rapidly, with the number of preprints posted to repositories each month almost doubling in the past year
Summary report from the Open Pharma workstream meetings in July
Open access publishing is on the rise, providing both opportunities and challenges for publishers, academics, funding bodies and pharma. However, academic authors collaborating with pharma prefer to publish in journals with the highest impact factor possible, and open access is not necessarily the authors’ priority. In our Open Pharma workstreams, we have identified a strong … Continue reading Open access education: time for a new approach?